FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
|Articles|October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
Author(s)Randi Hernandez
Pfizer's addition of a new vaccine suite and multiproduct bioprocess suite to its Ireland facility win the company the title of 2014 Facility of the Year.
Advertisement
The International Society for Pharmaceutical Engineers (ISPE) recognized Pfizer Ireland as the overall winner in the 2014 Facility of the Year Awards (FOYA) category at the society’s annual meeting in Las Vegas, Nevada. FOYA acknowledges the pharmaceutical manufacturing industry’s accomplishments in construction and facility design and the pursuit of new technologies.
The focus of Pfizer Ireland’s Network Strategy Implementation (NSI) Capacity project was the addition of a new vaccine suite and a drug substance bioprocess suite. The new manufacturing suites included the latest technologies, including electronic batch records, process analytical technology, and disposable bag processing. Pfizer Ireland conducted the project using a lean management strategy, a 5S program in the design process, and a Six Sigma toolkit. The Pfizer Ireland Grange Castle plant that won the award is located in Clondalkin, South County Dublin.
“The society was impressed with the NSI Capacity Expansion project and the company’s ability to effectively manage the challenges of maintaining supply with the demolition of existing facilities, new construction, and start-up and integration activities,” said Chair of the FOYA Judging Panel James Breen in a press release.
SOURCE: ISPE
Advertisement
Related to this article
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5